The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...